These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37242786)

  • 1. Development of Biopredictive Dissolution Method for Extended-Release Desvenlafaxine Tablets.
    Carapeto GV; Duque MD; Issa MG; Ferraz HG
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Extended-Release Mini-Tablets Containing Metoprolol Supported by Design of Experiments and Physiologically Based Biopharmaceutics Modeling.
    Issa MG; de Souza NV; Jou BWC; Duque MD; Ferraz HG
    Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.
    Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD
    J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
    Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
    Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harmonizing Biopredictive Methodologies Through the Product Quality Research Institute (PQRI) Part I: Biopredictive Dissolution of Ibuprofen and Dipyridamole Tablets.
    Tsume Y; Ashworth L; Bermejo M; Cheng J; Cicale V; Dressman J; Fushimi M; Gonzalez-Alvarez I; Guo Y; Jankovsky C; Lu X; Matsui K; Patel S; Sanderson N; Sun CC; Thakral NK; Yamane M; Zöller L
    AAPS J; 2023 Apr; 25(3):45. PubMed ID: 37085637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
    Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
    Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
    Aishwarya R; Murthy A; Ahmed T; Chachad S
    J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space.
    Bhattiprolu AK; Kollipara S; Ahmed T; Boddu R; Chachad S
    J Pharm Sci; 2022 Dec; 111(12):3397-3410. PubMed ID: 36096285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
    Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
    J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling.
    García MA; Bolger MB; Suarez-Sharp S; Langguth P
    J Pharm Sci; 2022 Jan; 111(1):262-273. PubMed ID: 34678271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.
    Kollipara S; Martins FS; Sanghavi M; Santos GML; Saini A; Ahmed T
    J Pharm Sci; 2024 Feb; 113(2):345-358. PubMed ID: 38043684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics - a case study and utility in regulatory justifications.
    Boddu R; Kollipara S; Bhattiprolu AK; Ahmed T
    Xenobiotica; 2023; 53(10-11):587-602. PubMed ID: 38062540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
    da Silva JD; de Sousa VP; Cabral LM; Davanço MG; Meulman J; de Oliveira Carvalho P; Campos DR
    AAPS PharmSciTech; 2020 Jul; 21(5):195. PubMed ID: 32666354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
    Wu D; Li M
    Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopredictive tools for the development of injectable drug products.
    Villa Nova M; Gan K; Wacker MG
    Expert Opin Drug Deliv; 2022 Jun; 19(6):671-684. PubMed ID: 35603724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
    Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
    AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification.
    Pepin X; McAlpine V; Moir A; Mann J
    Mol Pharm; 2023 Apr; 20(4):2181-2193. PubMed ID: 36859819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically relevant dissolution conditions towards improved in vitro - in vivo relationship - A case study with enteric coated pantoprazole tablets.
    Amaral Silva D; Gomes Davanço M; Davies NM; Krämer J; de Oliveira Carvalho P; Löbenberg R
    Int J Pharm; 2021 Aug; 605():120857. PubMed ID: 34229072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.
    Bermejo M; Hens B; Dickens J; Mudie D; Paixão P; Tsume Y; Shedden K; Amidon GL
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.